NAPSR News: Lilly's Diabetes Drug Better Than Sanofi's in Late-stage Trials

WASHINGTON - May 12, 2014 - PRLog -- Eli Lilly and Co. said its Type II diabetes drug was more effective than Sanofi SA's approved drug Lantus in reducing patients' blood sugar levels in 3 late-stage trials.

Lilly said while the main goal of the trials was to show that the drug, basal insulin peglispro, was as effective as Lantus, the trials showed the drug reduced blood sugar levels significantly more than Lantus.

Type II diabetes, the most common form of the disease, happens when the body does not use insulin properly, leading to high levels of blood sugar.

Basal insulin, or long-acting insulin therapies, are usually prescribed to keep blood sugar levels in control between meals.

Sanofi's Lantus is the world's most prescribed insulin product with quarterly worldwide sales of about $2 billion. The drug will lose U.S. patent protection in February 2015.

Lilly, which is counting heavily on new drug approvals to boost its fortunes, said it expected to file for European and U.S. regulatory approval for basal insulin peglispro by the end of first quarter of 2015.

Analysts expect Lilly's drug to reach sales of about $242 million by 2018, according to Thomson Reuters data.

Diabetes drugs have been Lilly's strong point for the past decade. But competition from new drugs, including those from Danish drugmaker Novo Nordisk, has hit the company's sales.

An estimated 382 million people worldwide have diabetes, according to the International Diabetes Federation, with Type II accounting for 90-95% of all cases. Type II diabetes is also closely linked with obesity.

The trials tested Lilly's drug in three patient groups: those who were not previously taking insulin, those who were taking mealtime insulin and those who were already taking another basal insulin.

All 3 groups were given Lilly's basal insulin and the results were compared with patients given Lantus.

Indianapolis-based Lilly's shares were trading flat at $59.31 in late morning trade on the New York Stock Exchange.

NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD!

With such industry leaders posting gains in profitability, they will need both certified and qualified individuals to sell their product. When industry leaders look for new candidates for entry level positions, they look toward individuals that are industry trained. Reason being that they are looking for people that have the background to sell their product both proficiently and efficiantly.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!

Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. The CNPR® represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative(CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information.